Skip to the page

Data / Form D filings / PHOTOPHARMICS INC

PHOTOPHARMICS INC: Form D filings

PHOTOPHARMICS INC, a biotechnology company in Lehi, UT, filed 10 Form D notices with the SEC between 2012 and 2025. The latest, on November 3, 2025, reports $26.2 million sold of a $26.3 million offering to 47 investors.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
3451 NORTH TRIUMPH BLVD, SUITE 201, Lehi, UT, 84043
Phone
(801) 358-0486
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1561150

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Nov 3, 2025Amendment$26,284,804$26,195,278$89,52647Oct 31, 2023sec.gov
Apr 18, 2025Amendment$23,884,807$23,883,208$1,59927Oct 31, 2023sec.gov
Nov 1, 2023New notice$17,884,813$16,109,791$1,775,02224Oct 31, 2023sec.gov
Dec 11, 2020New notice$2,500,000$2,500,0009Dec 4, 2020sec.gov
Oct 11, 2019New notice$6,644,601$6,644,60124Sep 27, 2019sec.gov
Mar 7, 2017New notice$2,750,000$2,650,566$99,43418Feb 24, 2017sec.gov
Feb 10, 2017New notice$2,327,991$2,327,99115Jan 31, 2017sec.gov
Jul 16, 2015New notice$2,700,000$2,060,000$640,00015Jun 12, 2015sec.gov
Jan 8, 2013New notice$3,111,165$2,079,992$1,031,17313Dec 27, 2012sec.gov
Nov 14, 2012New notice$330,000$330,0007Oct 31, 2012sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Gavin ChristensenDirector
Kent SavageExecutive Officer, Director
Daniel AdamsDirector

Other biotechnology companies in Utah that filed recently

Every Form D from the week of Nov 3, 2025 · All recent filings in Utah · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what PHOTOPHARMICS INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.